个人简介
Dr. Rose earned his Ph.D. at Stanford University in 1973 in the laboratory of Dr. Charles Yanofsky. His thesis research focused on regulation of the tryptophan operon of E. coli. He then did postdoctoral research at MIT in the laboratories of Drs. David Baltimore and Harvey Lodish, where he began work on eucaryotic RNA viruses. In 1978, Dr. Rose took a faculty position at the Salk Institute, where he continued work on RNA virus transcription, as well as structure, function, and transport of the vesicular stomatitis virus (VSV) glycoprotein. In 1986, he moved to become Professor of Pathology and Cell Biology at Yale University School of Medicine. In 1994, his laboratory developed a system for recovering non-segmented, negative-strand RNA viruses from DNA plasmids. His work at Yale during the past fifteen years has focused largely on new approaches to vaccine development using vectors based on recombinant VSV and other viral replicons. This work has led to development of robust vaccine platforms that can protect animals against numerous viral and bacterial pathogens, typically after a single dose. A VSV-based HIV vaccine advanced from the Rose laboratory has recently completed a successful Phase I clinical trial.
PhD Stanford University (1973)
BS Brandeis University (1969)
Fellow Massachusetts Institute of Technology
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains
Ryder, A. B., R. Nachbagauer, L. Buonocore, P. Palese, F. Krammer, and J. K. Rose (2016) J Virol 90:2544-2550
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder, A. B., L. Buonocore, L. Vogel, R. Nachbagauer, F. Krammer, and J. K. Rose. 2015. J Virol 89:2820-2830.
In vitro evolution of high-titer, virus-like vesicles containing a single structural protein
Rose, N. F., L. Buonocore, J. B. Schell, A. Chattopadhyay, K. Bahl, X. Liu, and J. K. Rose. 2014. Proc Natl Acad Sci U S A 111:16866-16871.
A Chimeric Vesiculo/alphavirus Is an Effective Alphavirus Vaccine
A. Chattopadhyay, Wang, E., Seymour, R., weaver S.C., Rose, J.K. (2013) J. Virol. 87:395-402
Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques.
Schwartz, J.A., Buonocore, L., Suguitan, A., Jr., Hunter, M., Marx, P.A., Subbarao, K., and Rose, J.K. (2011). J Virol 85, 4602-4605.
Significant Protection against High-Dose Simian Immunodeficiency Virus Challenge Conferred by a New Prime-Boost Vaccine Regimen.
Schell, J.B., Rose, N.F., Bahl, K., Diller, K., Buonocore, L., Hunter, M., Marx, P.A., Gambhira, R., Tang, H., Montefiori, D.C., et al. (2011). J Virol 85, 5764-5772.
Hybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectors.
Rose, N. F., Publicover, J., Chattopadhyay, A., and Rose, J. K. (2008). Proc Natl Acad Sci U S A. 105:5839-43.
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
Ramsburg, E, Rose, NF, Marx, PA, Mefford, M, Nixon, DF, Moretto, WJ, Montefiori, D, Earl, P, Moss, B & Rose, JK (2004) J Virol 78, 3930-3940.
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.
Rose, NF, Marx, PA, Luckay, A, Nixon, DF, Moretto, WJ, Donahoe, SM, Montefiori, D, Roberts, A, Buonocore, L & Rose, JK (2001) Cell 106, 539-549.
Okuma K, Fukagawa K, Kohma T, Takahama Y, Hamaguchi Y, Ito M, Tanaka Y, Buonocore L, Rose JK, Hamaguchi I: A recombinant vesicular stomatitis virus encoding CCR5-tropic HIV-1 receptors targets HIV-1-infected cells and controls HIV-1 infection. Microbes Infect. 2017 Apr - May; 2016 Dec 24. PMID: 28025070
Baquero E, Albertini AA, Raux H, Abou-Hamdan A, Boeri-Erba E, Ouldali M, Buonocore L, Rose JK, Lepault J, Bressanelli S, Gaudin Y: Structural intermediates in the fusion-associated transition of vesiculovirus glycoprotein. EMBO J. 2017 Mar 1; 2017 Feb 10. PMID: 28188244
van den Pol AN, Mao G, Chattopadhyay A, Rose JK, Davis JN: Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. J Virol. 2017 Mar 15; 2017 Feb 28. PMID: 28077641
Clarke DK, Hendry RM, Singh V, Rose JK, Seligman SJ, Klug B, Kochhar S, Mac LM, Carbery B, Chen RT, Brighton Collaboration Viral Vector Vaccines Safety Working Group.: Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 2016 Dec 12; 2016 Jul 6. PMID: 27395563
Nachbagauer R, Miller MS, Hai R, Ryder AB, Rose JK, Palese P, García-Sastre A, Krammer F, Albrecht RA: Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets. J Virol. 2015 Dec 30; 2015 Dec 30. PMID: 26719251
Ryder AB, Nachbagauer R, Buonocore L, Palese P, Krammer F, Rose JK: Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains. J Virol. 2015 Dec 16; 2015 Dec 16. PMID: 26676789
Reynolds TD, Buonocore L, Rose NF, Rose JK, Robek MD: Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection. J Virol. 2015 Oct; 2015 Aug 5. PMID: 26246574
京公网安备 11010802027423号